EUVIMEDEUVIMED entdecken
Crossref

Chlorogenic acid attenuates idiopathic pulmonary fibrosis: An integrated analysis of network pharmacology, molecular docking, and experimental validation

Juan Manuel Velázquez-Enríquez, Jovito Cesar Santos-Álvarez, Alma Aurora Ramírez-Hernández, Edilburga Reyes-Jiménez, Laura Pérez-Campos Mayoral, María de Los Ángeles Romero-Tlalolini, Cristian Jiménez-Martínez, Jaime Arellanes-Robledo, Saúl Villa-Treviño, Verónica Rocío Vásquez-Garzón, Rafael Baltiérrez-Hoyos

Biochemical and Biophysical Research Communications · 2024

DOI: 10.1016/j.bbrc.2024.150672 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Juan Manuel Velázquez-Enríquez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Fibrosis y Cáncer, Facultad de Medicina y Cirugía, Universidad Autónoma Benito Juárez de Oaxaca, Ex Hacienda de Aguilera S/N, Sur, San…. Hauptthemen laut MEDLINE: Chlorogenic Acid, Molecular Docking Simulation, Idiopathic Pulmonary Fibrosis, Network Pharmacology. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 113 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung condition, the cause of which remains unknown and for which no effective therapeutic treatment is currently available. Chlorogenic acid (CGA), a natural polyphenolic compound found in different plants and foods, has emerged as a promising agent due to its anti-inflammatory, antioxidant, and antifibrotic properties. However, the molecular mechanisms underlying the therapeutic effect of CGA in IPF remain unclear. The purpose of this study was to analyze the pharmacological impact and underlying mechanisms of CGA in IPF. MAIN METHODS: Using network pharmacology analysis, genes associated with IPF and potential molecular targets of CGA were identified through specialized databases, and a protein-protein interaction (PPI) network was constructed. Molecular docking was performed to accurately select potential therapeutic targets. To investigate the effects of CGA on lung histology and key gene expression, a murine model of bleomycin-induced lung fibrosis was used. KEY FINDINGS: Network pharmacology analysis identified 384 were overlapped between CGA and IPF. Key targets including AKT1, TP53, JUN, CASP3, BCL2, MMP9, NFKB1, EGFR, HIF1A, and IL1B were identified. Pathway analysis suggested the involvement of cancer, atherosclerosis, and inflammatory processes. Molecular docking confirmed the stable binding between CGA and targets. CGA regulated the expression mRNA of EGFR, MMP9, AKT1, BCL2 and IL1B and attenuated pulmonary fibrosis in the mouse model. SIGNIFICANCE: CGA is a promising multi-target therapeutic agent for IPF, which is supported by its efficacy in reducing fibrosis through the modulation of key pathways. This evidence provides a basis to further investigate CGA as an IPF potential treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chlorogenic AcidMolecular Docking SimulationIdiopathic Pulmonary FibrosisNetwork PharmacologyAnimalsMiceProtein Interaction MapsMice, Inbred C57BLHumansMaleBleomycinLung

Stichwörter der Autor:innen

AntifibroticChlorogenic acidDrug discoveryIdiopathic pulmonary fibrosisNetwork pharmacologyPulmonary disease

Substanzen

Chlorogenic AcidBleomycin

Autor:innen und Institutionen

  • Laboratorio de Fibrosis y Cáncer, Facultad de Medicina y Cirugía, Universidad Autónoma Benito Juárez de Oaxaca, Ex Hacienda de Aguilera S/N, Sur, San Felipe del Agua, Oaxaca, C.P. 68020, Mexico. Electronic address: juan…
  • Laboratorio de Fibrosis y Cáncer, Facultad de Medicina y Cirugía, Universidad Autónoma Benito Juárez de Oaxaca, Ex Hacienda de Aguilera S/N, Sur, San Felipe del Agua, Oaxaca, C.P. 68020, Mexico.
  • Facultad Medicina y Cirugía, Universidad Autónoma Benito Juárez de Oaxaca, Ex Hacienda de Aguilera S/N, Sur, San Felipe del Agua, Oaxaca, C.P. 68020, Mexico.
  • CONAHCYT-Facultad de Medicina y Cirugía, Universidad Autónoma Benito Juárez de Oaxaca, Ex Hacienda de Aguilera S/N, Sur, San Felipe del Agua, Oaxaca, C.P. 68020, Mexico.
  • Departamento de Ingeniería Bioquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Unidad Profesional Adolfo López Mateos, Zacatenco, Av. Wilfrido Massieu Esq. Cda. Miguel Stampa S/N, Alcald…
  • Laboratorio de Enfermedades Hepáticas, Instituto Nacional de Medicina Genómica - INMEGEN, México City, 14610, Mexico; Dirección Adjunta de Investigación Humanística y Científica, Consejo Nacional de Humanidades, Ciencia…

Zitieren

APA

Velázquez-Enríquez, J. M., Santos-Álvarez, J. C., Ramírez-Hernández, A. A., Reyes-Jiménez, E., Pérez-Campos Mayoral, L., Romero-Tlalolini, M. L. Á., Jiménez-Martínez, C., Arellanes-Robledo, J., Villa-Treviño, S., Vásquez-Garzón, V. R., & Baltiérrez-Hoyos, R. (2024). Chlorogenic acid attenuates idiopathic pulmonary fibrosis: An integrated analysis of network pharmacology, molecular docking, and experimental validation. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150672

Vancouver

Velázquez-Enríquez JM, Santos-Álvarez JC, Ramírez-Hernández AA, Reyes-Jiménez E, Pérez-Campos Mayoral L, Romero-Tlalolini MLÁ, et al. Chlorogenic acid attenuates idiopathic pulmonary fibrosis: An integrated analysis of network pharmacology, molecular docking, and experimental validation. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150672

BibTeX
@article{VelzquezEnrquez2024,
  author = {Velázquez-Enríquez, Juan Manuel and Santos-Álvarez, Jovito Cesar and Ramírez-Hernández, Alma Aurora and Reyes-Jiménez, Edilburga and Pérez-Campos Mayoral, Laura and Romero-Tlalolini, María de Los Ángeles and Jiménez-Martínez, Cristian and Arellanes-Robledo, Jaime and Villa-Treviño, Saúl and Vásquez-Garzón, Verónica Rocío and Baltiérrez-Hoyos, Rafael},
  title = {Chlorogenic acid attenuates idiopathic pulmonary fibrosis: An integrated analysis of network pharmacology, molecular docking, and experimental validation},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  doi = {10.1016/j.bbrc.2024.150672}
}
Kostenlos starten →